RxDoctor Payments Data

Gary Carlson, MD

Internal Medicine · Newport Beach, CANPI 1497700116

Payments from drug & device makers

$11,374in general payments, 2019–2025

Across 570 payments — averaging $19.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • AbbVie$1K
  • Lilly USA, LLC$1K
  • Boehringer Ingelheim$889
  • Pfizer$818
  • Amgen$758
  • plus $5K from 47 others

What the payments were for

  • Food & beverage$11,374100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$11,374 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$100,063
Medicare patients
292
Services billed
1,184

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban121$117,014
OzempicSemaglutide62$61,150
JardianceEmpagliflozin53$57,145
JanuviaSitagliptin Phosphate44$55,470
CreonLipase/Protease/Amylase14$41,448
FarxigaDapagliflozin Propanediol32$38,951
MounjaroTirzepatide31$30,856
XareltoRivaroxaban24$29,718
TrulicityDulaglutide24$26,767
TradjentaLinagliptin16$13,784
JanumetSitagliptin Phos/Metformin Hcl11$13,207
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$12,850
GemtesaVibegron14$10,076
SynthroidLevothyroxine Sodium88$8,601
Rosuvastatin Calcium390$7,943

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$818$119,873172 claims
Boehringer IngelheimJardiance, Tradjenta$889$70,92969 claims
MerckJanuvia, Janumet$555$68,67755 claims
Novo NordiskOzempic$625$61,15062 claims
Lilly USA, LLCMounjaro, Trulicity$1,236$57,62455 claims
AbbVieCreon, Synthroid$1,295$50,050102 claims
AstraZenecaFarxiga$1,485$38,95132 claims
Johnson & JohnsonXarelto$463$29,71824 claims
GSKTrelegy Ellipta, Breo Ellipta$194$19,35734 claims
Sumitomo Pharma America, Inc.Gemtesa$42$10,07614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Newport Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →